Background: There are large regional variations in the prevalence and mortality of cardiovascular disease in general populations in China. It remains uncertain whether the prevalence in type 2 diabetes mellitus (T2DM) varies by region in China.
C hina has experienced a rapid increase in the prevalence of diabetes in the past three decades (1) (2) (3) . Cardiovascular disease (CVD) was one of the most severe complications in type 2 diabetes mellitus (T2DM) and one-quarter of deaths in T2DM was attributable to CVD (4) . Several large studies (n . 66,000) in the United States (5), Sweden (6) , and a multinational study in 28 countries across Asia, Africa, Europe, and South America (7) reported that the prevalence of CVD in T2DM ranged from 21.6% to 34.2%. A population-based study from South Western Germany showed that the prevalence of coronary heart disease (CHD) and stroke in patients with T2DM were 23.0% and 4.2%, respectively (8) . A China national survey in the general population showed that the age-standardized prevalence of CHD, stroke, and composite of both in 2007-2008 was 0.60%, 0.80%, and 1.37% in China mainland (9) . Four studies reported the prevalence of CVD in Chinese patients with T2DM. A Taiwan study (n = 16,994) reported that the prevalence of stroke was 2.3% in patients with T2DM, whereas the prevalence of stroke was only 0.6% in the general population in Taiwan in 2002 (10) . On the other hand, a study from Beijing (n = 4629) reported a 5.5% of prevalence of stroke in patients with T2DM in 2012 (11) . A smaller study (n = 1524) showed that the crude prevalence of CVD in T2DM was 33.4% in four Chinese cities (Shanghai, Chengdu, Beijing, and Guangzhou) in 2007 (12) . The crude prevalence of CVD in 2010 among the 11,019 Chinese participants with T2DM from 130 urban hospitals in China who were enrolled in the above multinational study was 21.3%, remaining the lowest among the surveyed regions including South Asia and East Asia (7, 13) . Indeed, previous studies only reported prevalence of CHD and stroke in T2DM in limited and specific areas of China due to their location specificity and relative small population sizes. Given to the huge number of people with T2DM in China, it is essential to know the true prevalence of CHD and stroke in T2DM in China for estimation of the disease burden from T2DM.
We analyzed the data of the China's largest database of patients with T2DM, China National HbA1c Surveillance System (CNHSS), to address: (1) regional differences in the prevalence of CHD and stroke; (2) whether provincial per capita income levels were independently associated with the risks of CHD and stroke; and (3) whether geographic location of residence was independently associated with the risks of CHD and stroke among patients with T2DM in China.
Materials and Methods

Study population
We used data from the CNHSS that was set up by the Chinese Diabetes Society in 2009 to monitor glycemic control among outpatients with T2DM in China. In this analysis, the data collected from 1 April 2012 to 30 June 2012 were retrieved from the main CNHSS database. The study design and methods of the CNHSS were published previously (14, 15) . Briefly, 630 hospitals (486 tertiary care hospitals, 32 secondary care hospitals, and 12 primary care hospitals) located in 106 cities of 30 provincial administrative regions of mainland China participated in the survey in 2012. The inclusion criteria included the following: being an outpatient with T2DM and being treated with antidiabetes medications; aged 18 years or older; having at least one previous outpatient medical record for diabetes; and being a local resident for at least 6 months consecutively before participation in the study. The exclusion criteria included the following: inpatients; having type 1 diabetes; having diabetes secondary to other diseases; being on diet and other lifestyle therapy or receiving Chinese herbal medicine only; being pregnant or breastfeeding; being unable to communicate due to unconsciousness or mental diseases. During the survey period, we sequentially invited the first seven patients with T2DM who visited the clinic of the participating hospitals as outpatients who met the inclusion criteria but did not have any of the exclusion criteria to participate in the survey. The recruitment was going on until the participating hospital recruited 400 qualified patients or reached the survey end date, 30 June 2012, whichever came earlier. A total of 223,612 patients with T2DM were retrieved from the main database for the current analysis. We calculated hospital-specific rates of CHD and stroke and excluded all the patients from the hospitals if their rates of either CHD or stroke exceeded the mean +/2 4 SDs. This procedure led to exclusion of 4090 patients from 12 hospitals in Heilongjiang, Jiangxi, Henan, Ningxia, Hainan, and Anhui. The remaining 219,522 patients with T2DM were used in the final analysis.
The Ethics Committee of the Chinese People's Liberation Army General Hospital approved the current study. Informed consent was obtained from all patients before data collecting.
Procedures
As described in previously published reports (14, 15) , the medical notes, including diagnosis of T2DM, results of laboratory assays and use of antidiabetes medications, were reviewed by trained fieldworkers such as postgraduate medical students or nurses. All data were recorded in a form, including age, sex, height, weight, blood pressure (BP), and date of diagnosis of diabetes. Patients reported whether they were diagnosed with any comorbidities or diabetic complications, including hypertension, dyslipidemia, CHD, stroke, and other complications. All laboratory assessments were done in the local hospitals, where the patients were interviewed. Laboratory data for blood glucose, glycated hemoglobin (HbA1c), and lipids within 30 days before or 7 days after the survey were retrieved and recorded. Specific information about treatments used for management of T2DM was documented, including use of oral antidiabetes medications, different types of insulin, and combined use of these medications. Staff members entered and uploaded all the data onto a central database. Strict quality control measures were in place during the whole fieldwork period. Fieldworkers were trained in workshops to standardize data collection procedures. All the completed forms and enter data were checked for consistency and possible logistic errors. Random samples of the uploaded data (5%) were periodically extracted from the Electronic Data Capture System for rechecking of their quality.
Ascertainment of outcomes
As reported earlier (14) , prior history of CHD and date of the diagnosis were retrieved from the patient database. Medical records from secondary or tertiary hospitals were used to define previous CHD, including ischemic heart disease with abnormal electrocardiogram or stress test, myocardial infarction with typical changes in electrocardiogram and plasma enzyme testing, coronary revascularization, percutaneous transluminal coronary angioplasty, or coronary atherectomy. Prior diagnosis of stroke was ascertained by reviewing medical records from secondary or tertiary hospitals. Stroke was defined as having ischemic or hemorrhagic stroke, i.e., subarachnoid hemorrhage, intracerebral hemorrhage, and other or unspecified intracranial hemorrhage, no matter whether the patient had completely or incompletely recovered from stroke. The definitions of diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy were also available elsewhere (15) .
Statistical analysis
The data were analyzed using the Statistical Analysis System Release 9.1 (SAS Institute, Inc., Cary, NC) unless specified. The continuous variables were expressed as mean and SD or median and interquartile range where appropriate. Categorical variables were expressed as percentage and numbers. Normal distribution of continuous variables was tested by checking their quantile-quantile plot. Categorical variables were compared by using x 2 test. Analysis of variance or Mann-Whitney U test if normal distribution was rejected was used to compare continuous variables or ordinal variables among groups. Body mass index (BMI) was calculated as body weight in kilograms divided by squared height in meters. The social economic development level was estimated by provincial per capita incomes in 2013 (16) . The 30 participating provinces or provincial administrative areas, i.e., the four cities under direct administration of the China central government, were classified into tertiles, i.e., high ($ CNY￥18,000), middle (CNY￥15,000 to 17,999), and low (, CNY￥15,000) per capita income provinces and classified into Northeast, North, East, South, Central, Northwest, and Southwest by their geographic locations within China.
We calculated the age and sex standardized prevalence of CHD and stroke and composite of both among patients with T2DM by province, provincial per capita income, and geographic region. The direct method and population distribution of China from the recent national population census of China in 2010 (17) were used to perform the standardization. The age and sex standardized prevalence of CHD, stroke, and composite of both was plotted using Geospatial Information System (ArcGIS) 10.2 (ESRI, Redlands, CA).
Logistic regression was used to determine ORs and 95% CIs of provinces (against the province with the lowest risk of either of CHD or stroke), provincial per capita income levels (against the low provincial per capita income level), and geographic regions (against the region with the lowest risk of either CHD or stroke). A structured adjustment scheme was performed to check whether the increased risks could be attenuated by adjustment for potential confounders. First, we adjusted for age, sex, and hospital levels (primary, secondary, and tertiary hospitals as described previously) (14) (model 1). Then, we adjusted for clinical factors, including duration of diabetes, BMI, HbA1c, BP, lipid profile, self-monitoring of blood glucose, and antidiabetes medications to check whether the differences in these clinical factors could explain the differences in the risks of CHD or stroke (model 2). At last, we adjusted for geographic region in the provincial per capita income models and adjusted for provincial per capital income levels in the geographic region models to check their independent associations with CHD or stroke (model 3). P values less than 0.05 were considered as statistical significance.
Results
Population characteristics
The 219,522 patients included in the analysis had a mean age of 58.4 years (SD, 11.4) and a median duration of diabetes of 4.01 (25th to 75th percentiles: 1.77 to 8.20) years. Males accounted for 53.7% of the patients. Of them, 11.01% (n = 24,179) had CHD, 4.27% (n = 9366) had stroke, and 13.78% (n = 30,240) had composite of both. Of these patients, 46.14% were overweight and 10.79% were obese. The rates of not reaching the glycemic (i.e., HbA1c $ 7.0%), BP (i.e., $140/90 mm Hg) and low-density lipoprotein cholesterol (LDL-C; i.e., $2.6 mmol/L) treatment targets were quite high, 69.74%, 39.91%, and 59.20%, respectively. Consequently, only 9.04% had achieved all the three treatment targets and 31.92% had achieved two of the treatment targets (Appendix Table 1 ).
Differences in clinical risk factors by region and provincial per capita income level
There were significant differences in all the variables among patients who lived in different geographical regions (Table 1) . Patients residing in Northeast and in North were more likely to have higher BMI, to be overweight or have obesity, to have longer durations of diabetes, to have higher BP, and higher LDL-C than their counterparts in other regions. Patients in Northeast and North were less likely to achieve the treatment targets of BP and LDL-C control. Patients in the two regions were less likely to have achieved three and two treatment targets of HbA1c, BP, and lipid control although they did not have the highest HbA1c, the lowest high-density lipoprotein cholesterol (HDL-C), and the highest triglyceride and did not have the highest rates of achievement of treatment targets of HDL-C control (i.e., .1.0 mmol/L in men and .1.3 mmol/L in women) and triglyceride control (i.e., ,1.7 mmol/L). Northeast and North only had 6.9% and 7.3% of patients to have achieved all the three treatment targets. Patients in the two regions were more likely to use one oral antidiabetes medication, whereas patients in other regions were more likely to use multiple oral antidiabetes medications.
There were also large differences in all these variables by provincial income level per capita. Cardiovascular risk factors tended to be more prevalent in the high provincial income per capita group than the low provincial income level per capita group (Appendix Table 1 ).
Overall prevalence of CHD, stroke, and composite of both in patients with T2DM in China
The age standardized prevalence of CHD were 4.43% (95% CI, 4.41% to 4.44%) in male and 4.76% (4.75% to 4.78%) in female patients (Table 2) , and the age standardized prevalence of stroke was 1.74% (1.73% to 1.75%) in male and 1.85% (1.84% to 1.86%) in female patients (Table 3) . Putting them together, the standardized prevalence of either CHD or stroke was 5.67% (5.65% to 5.69%) in male and 6.04% (6.02% to 6.06%) in female patients (Table 4) Prevalence and risks of CHD, stroke, and composite of both in T2DM by province There were marked differences in the age-and sexstandardized prevalence of CHD, stroke, and composite of both in patients with T2DM by province (Tables 2-4 ; Fig. 1 ). Tianjin had the highest standardized prevalence of CHD (11.27%; 95% CI, 11.21 to 11.33), followed by Jilin, Shandong, Heilongjiang, Liaoning, and Beijing. Heilongjiang had the highest prevalence of stroke (3.57%; 95% CI, 3.53 to 3.60), followed by Tianjin, Liaoning, Henan, Inner Mongolia, Beijing, and Shandong. Taken together, Tianjin had the highest prevalence of composite of CHD and stroke (12.85%; 95% CI, 12.79 to 12.92), followed by Jilin, Shandong, Heilongjiang, Liaoning, and Beijing.
After further adjustment for traditional clinical risk factors, Tianjin, Jilin, Shandong, Heilongjiang, Liaoning, and Beijing were among the provinces with the highest adjusted ORs for CHD (adjusted ORs $ 2.3). In addition, the adjusted ORs of Hunan and Shaanxi vs Hainan were also $ 2.3. Tianjin, Jilin, Shandong, Heilongjiang, Liaoning, and Beijing also had 2.4 and more fold stroke risks of Hainan. In addition, Henan and Guangxi were among the provinces that had the highest adjusted ORs for stroke (adjusted ORs $ 2.4). Taken together, Jilin had the highest adjusted OR of composite of CHD and stroke (3.74; 95% CI, 2.69 to 5.19), Shandong (3.30; 2.39 to 4.56), Tianjin (3.25; 2.36 to 4.49), and Heilongjiang (3.10; 2.22 to 4.34) were among the second highest risks of composite of CHD and stroke (ORs . 3.0). The atlas of standardized prevalence of CHD, stroke, and composite of both is showed in Fig. 1 .
Prevalence and risks of CHD, stroke, and composite of both in T2DM by provincial per capita income level
The age-and sex-adjusted prevalence of CHD, stroke, and composite of both tended to increase with increased c Further adjusted for duration of diabetes, BMI, HbA1c, SBP, LDL-C, HDL-C, triglyceride, self-monitoring of blood glucose, and use of antidiabetes medications as listed in Table 1 .
provincial per capital income levels (Appendix Table 2 ). The ORs of high provincial per capita income vs low provincial per capita income for composite of both remained significant after further adjustment for levels of hospitals. Additional adjustment for traditional risk factors and use of antidiabetes medications enhanced the effect sizes of high and middle provincial per capita income levels for CHD, stroke, and composite of both. However, further adjustment for regions reversed the effects of high and middle provincial per capita income levels for CHD, turning out to be protective.
Prevalence and risks of CHD, stroke, and composite of both in T2DM by geographic region There were marked differences in the age-and sexstandardized prevalence of CHD, stroke, and composite of both in patients with T2DM by geographic region (Table 5 ). Northeast had the highest standardized prevalence of CHD (7.46%; 95% CI, 7.41% to 7.51%), stroke (2.86%; 2.83% to 2.89%), and composite of both (9.00%; 8.95% to 9.05%). North had the second highest standardized prevalence of CHD (7.30%; 95% CI, 7.25% to 7.35%), stroke (2.55%; 2.52% to 2.58%), and composite of both (8.91%; 8.86% to 8.97%).
Using Southwest, which had the lowest prevalence of composite of CHD and stroke, as the referent region, and after further adjustment for levels of hospitals, Northeast and North had markedly increased risks of CHD, stroke, and composite of both. The statistical significance persisted after further adjustment for traditional risk factors and use of antidiabetes medications (ORs of Northeast To ascertain that the ORs of Northeast and North were statistically higher than other regions, we repeated the same multivariable analysis with use of a different region as the reference in rotation. Northeast and North had significantly higher risks of CHD, stroke, and composite of both than any other regions (P , 0.0001) and Northeast even had statistically higher risks of CHD (1.15, 1.10 to 1.21), stroke (1.15, 1.07 to 1.24), and composite of both (1.17, 1.11 to 1.23) than North. In fact, all the ORs of comparisons between any two regions were statistically significant except for the OR of Northwest vs Southwest for stroke (Appendix Tables 3-8) .
Discussion
Using the largest database of patients with T2DM in China, we found the following: (1) there were very low rates of achieving the HbA1c, BP, and LDL-C treatment a Age and sex standardized prevalence.
b Adjusted for age, sex, and levels of hospitals.
c Further adjusted for duration of diabetes, BMI, HbA1c, SBP, LDL-C, HDL-C, triglyceride, self-monitoring of blood glucose, and use of antidiabetes medications as listed in Table 1 .
targets in China and consequently, a very high overall prevalence of CHD, stroke, and composite of both in the population with T2DM, which were in contrast to their low rates in the general population in China (9); (2) the Northeast and North patients with T2DM had markedly higher BMI, BP, and LDL-C, and consequently, had high rates of obesity and lower rates of achieving BP and LDL-C targets; and (3) there was a large variation in the risks of CHD, stroke, and composite of both by province and region, which could not be entirely explained by traditional risk factors and provincial per capita income levels. It is well established that T2DM predisposes patients to high risk of macrovascular disease (6, 8) , which are supported by surveys in China (10, 11) . This study further confirmed that there was a huge increased burden of CHD and stroke from T2DM in China (3). More importantly, our study revealed a large variation in the risks of CHD and stroke in T2DM in China. Patients with T2DM in Northeast and North had substantially increased risks of CHD and stroke, and the elevated risks were even higher than that in early onset T2DM (14) . Large clinical trials have demonstrated that tight control of hyperglycemia, high BP, and abnormal lipid profile can substantially reduce the risk of macrovascular disease in T2DM (18, 19) . Indeed, achievement of treatment targets of HbA1c, BP, and lipids have become the corner stone in the management of patients with T2DM. In this regard, we observed that patients in the Northeast and North regions had lower rates than in other regions to have achieved these treatment targets, especially, the BP target and LDL-C target. The low rates of the target achievement partially explained the increased risks of CHD and stroke in patients with T2DM in Northeast and North. However, most of the increased risks of CHD and stroke in the two regions could not be explained by the levels of these traditional cardiovascular risk factors.
It is well known that there is a large variation in the risk of CHD and stroke in the world (20) . In China, a national survey of the general population in 2013 (n . 0.48 million) reported that Northeast had the highest rates of incidence and mortality of stroke, whereas Southwest had the lowest rates of stroke incidence and mortality (21) . Similarly, another study in China reported that Northeast and North had the highest mortality of ischemic heart disease and stroke in the general population in 2013 (22) . In a large cohort with T2DM, our study observed a similar regional pattern of prevalence of CHD and stroke in China. The similarity is not limited to the large geographic regions but also at provincial levels. For example, Jilin, Heilongjiang and Liaoning, Tianjin, and Beijing were among the provinces that had the highest prevalence and risks of CHD and stroke. It is also interesting to note that high developed levels were associated with increased risk of diabetes in China (2) . Our study also found that the high provincial per capita income level was associated with increased risks of CHD and stroke in T2DM. However, the elevated risks of CHD and stroke were greatly attenuated by adjustment for geological regions, which suggests that the differences in the risks of CHD and stroke by geological regions explained the differences by provincial per capita income levels.
Because the residual risks of CHD and stroke by region were substantial after adjusting for traditional risk factors and provincial per capita income levels, it is critically important to know the underlying reasons for the large variation in the risks of CHD and stroke in T2DM by region. First, lifestyle such as diet and physical activity are associated with the risk of CVD in the general population (23) as well as in subjects with impaired glucose tolerance (24, 25) . The 3B Study (26) found that poor lifestyle led to increased prevalence of cardiovascular risk factors in Chinese population with T2DM, and the increased levels of cardiovascular risk factors are deemed to increase the risks of CHD and stroke. Second, cold ambient temperature was found to be associated with increased risk of myocardial infarction in the general population (27, 28) , which, presumably, may also work for patients with T2DM. Third, the general population in China had a very high dietary salt intake and the mean weighed salt intake of a standard person was as high as 9.1 g per day (29) . The Northeast and North regions had the highest salt intake among the geographic regions in China in 2006-2010 (sodium intake per day: 6.1 g in Northeast and North regions; 4.5 g in South; 4.6 g in East; and 5.4 g in Southwest and Northwest) (30) . In this regard, a meta-analysis of 177,025 participants enrolled in 19 independent cohort samples with 11,000 and more vascular events reported that high salt intake was associated with markedly increased risk of stroke and total CVD (31) . A group from the United States used the CHD Policy Model and estimated that a reduction in dietary salt intake of up to 3 g per day could substantially reduce cardiovascular events and medical costs (32) . Salt intake reduction has also been a key (34) . Although a study has reported that genes ABCA1-G596A and CETPtaq1B had a regional difference in gene frequency in China (35) , there are no studies reporting that these known genetic variants associated with macrovascular disease in T2DM differed by region in China. Indeed, this is one area that is worth further investigation. Our study has strong clinical and public health implications for prevention of CHD and stroke in patients with T2DM in China. China had 114 million adults living with T2DM in 2010 (3), and T2DM greatly increased the burden of CHD and stroke. The controlled rates of HbA1c, BP, and LDL-C were quite low in patients with T2DM in China, especially in Northeast and North regions, and large randomized controlled trials have demonstrated that tight control of HbA1c, BP, and lipids can substantially reduce the risk of CVD in T2DM (18, 19) . China, especially the Northeast and North, should make great efforts to achieve the treatment targets of HbA1c, BP, and lipid control. Such efforts are expected to substantially reduce the burden of CHD and stroke from T2DM in China. Notwithstanding, as showed in our study, there was a large residual risk of CHD and stroke after adjustment for traditional risk factors. Further multipopulation studies in China are warranted to investigate risk factors that led to the huge regional differences in CHD and stroke risks in T2DM. Identification of those factors would be an important step toward a further large reduction in the risks of CHD and stroke in T2DM in China.
The study has several limitations. First, our survey sites only included cities and our findings may not be applicable to the rural areas of China. Second, our survey was not a random sampling survey. Although careful standardization and various adjustments were made, the reported prevalence and relative risks may slightly differ from true values. Third, the patients in our survey were all on antidiabetes medications and those patients who were on diet treatment only were not invited to participate. As the patients on diet treatment only were at low risk of CHD and stroke, exclusion of these patients may lead to overestimating of the prevalence. Fourth, use of statins and antihypertensive medications were not documented. However, the validation study in our previous analysis showed that impacts of nonadjustment for use of these medications were small (14) . Fifth, our survey did not collect duration of residence and migrant worker status in our patients and we could not differentiate migrant workers from local residents. In this regard, a study (36) showed that most metabolic risk factors were less prevalent in migrant workers than in the general population of China. Therefore, the possibility cannot be excluded that the difference in migrant workers by region could partially contribute to the regional differences in CHD and stroke risks in China. Sixth, use of antidiabetes medications was influenced by actual compliance and some prescribed medications were not actually used. We also noticed that our study was a cross-sectional survey. The effects of these medications on clinical outcomes in observational studies were subject to three major biases, prevalent user bias, immortal time bias, and drug use indication bias (37) . Therefore, the observed associations between use of these medications and clinical outcomes in this survey did not suggest any treatment effects.
In conclusion, we found large regional differences in the prevalence and risks of CHD and stroke in patients with T2DM in China. Further studies with recruitment of subjects with T2DM from multiple populations in China are warranted to investigate risk factors responsible for the large regional differences in the risks of CHD and stroke in T2DM in China. Eventual control of those risk factors would be important steps toward a large reduction in the macrovascular disease burden from T2DM in China.
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